Ipsen Pharma S.a.s.

Societe De Conseils De Recherches Et D'applications Scientifiques Sas

Louisiana State University and Agricultural & Mechanical College

Biomeasure Incorporated

Cedars-sinai Medical Center

Societe De Conseils De Recherches Et D'applications Scientifiques (s.c.r.a.s.)

The Administrators of the Tulane Educational Fund

Università Degli Studi Di Ferrara

Ipsen Pharma

Michael DeWitt Culler

David H Coy

Zheng Xin Dong

Sun H Kim

Jacques-Pierre Moreau

Andrew A Butler

Heather A Halem

Philip G Kasprzyk

Yeelana Shen

Yeelena Shen

Giovanni Tulipano

Andrea Giustina

Barry A Morgan

Christophe Thurieau

Thomas D Gordon

Shlomo Melmed

Jeanne Mary Comstock

Romano Danesi

Rakesh Datta

Jundong Zhang

Guido Bocci

Mario Deltacca

John E Taylor

Ilan Shimon

Maria Chiara Zatelli

Sun Hyuk Kim

Christophe Alain Thurieau

Ettore C Degli Uberti

Ettore Ciro Degli Uberti

The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.

Use of melanocortins to treat insulin sensitivity

The present invention relates to peptide ligands of the melanocortin receptors, in particular the melanocortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.

The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogous of native hGhrelin.

Method for inhibiting inflammation and pre-inflammatory cytokine/chemokine expression using a ghrelin analogue

The invention features somatostatin-dopamine chimeric analogs and methods relating to their therapeutic use for the treatment of neoplasia, acromegaly, and other conditions.

Somatostatin-dopamine chimeric analogs

A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, H-Inp-D-Bal-D-Trp-Phe-Apc-NH(SEQ ID NO:73) or other suitable ghrelin agonist, to counteract the catabolic effects of dexamethasone and other natural glucocorticoids.

Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment

Disclosed is a series of somatostatin-dopamine chimeric analogs which retain both somatostatin and dopamine activity in vivo. An example is: 6-n-propyl-8&#x3b2;-ergolinglmethylthioacetyl-D-Phe-c(Cys-Tyr-D-Trp-Lys-Abu-Cys)-Thr-NH.

The invention comprises peptidyl analogs according to formulae (I) or (II) as depicted below: wherein the definitions of Ato Aand Rto Rare provided for in the specification for each of formulae (I) and (II), pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising an effective amount of a compound of formula (I), that possess agonist or antagonist ghrelin activity, along with therapeutic and non-therapeutic uses thereof.

Analogs of ghrelin

The invention features targeted cytotoxic compounds and methods relating to their therapeutic use for the treatment of neoplasia and other conditions.

Peptide-cytotoxic conjugates

A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, [Aib, Glu(NH-hexyl)]hGhrelin(1-28)-NH(SEQ ID NO:2) or other suitable ghrelin agonist, to counteract the catabolic effects of said dexamethasone and other natural glucocorticoids.

Disclosed is a series of somatostatin-dopamine chimeric analogs which retain both somatostatin and dopamine activity in vivo. An example is: 6-n-propyl-8&#x3b2;-ergolinglmethylthioacetyl-D-Phe-c-(Cys-Tyr-D-Trp-Lys-Abu-Cys)-Thr-NH.

Disclosed is a series of somatostatin-dopamine chimeric analogs which retain both somatostatin and dopamine activity in vivo. An example is:

The present invention relates to a method of inhibiting fibrosis in a patient. The method comprises administering a therapeutically effective amount of a somatostatin, a somatostatin agonist or apharmaceutically acceptable salt thereof to said patent.

Growing community of inventors

Hopkinton, MA, United States of America

Michael DeWitt Culler